Search results for "33"

showing 10 items of 1917 documents

Expectation Damages and Bilateral Cooperative Investments

2012

We examine the efficiency of the standard breach remedy expectation damages in a setting where the buyer invests cooperatively and the seller invests both cooperatively and selfishly. Contracts may specify a required quality level and an upper bound to the seller's coordination costs. We find that it is optimal to write an augmented Cadillac contract in which quality is stipulated such that it cannot be met with positive probability together with a very low price. Thus, the seller becomes a residual claimant and the coordination-cost threshold can be used to balance the incentives of the buyer.

media_common.quotation_subjectjel:D86Upper and lower boundsMicroeconomicsEconomicsddc:330C70Production (economics)Incomplete contractsQuality (business)Residual claimantPositive probabilitymedia_commonjel:C70Actuarial scienceK12TheoryofComputation_GENERALInvestment (macroeconomics)jel:K12IncentiveBalance (accounting)ComputingMilieux_COMPUTERSANDSOCIETYQuality levelBusinessExpectation damagesD86LawFinanceAmerican Law and Economics Review
researchProduct

We are the people and you are fake news: a social identity approach to populist citizens’ false consensus and hostile media perceptions

2018

This study aims to investigate the relationships between citizens’ populist attitudes, perceptions of public opinion, and perceptions of mainstream news media. Relying on social identity theory as an explanatory framework, this article argues that populist citizens assume that public opinion is congruent with their own opinion and that mainstream media reporting is hostile toward their own views. To date, only anecdotal evidence suggests that both assumptions are true. The relationships are investigated in a cross-sectional survey with samples drawn from four Western European countries ( N = 3,354). Multigroup regression analysis supports our hypotheses: False consensus and hostile media p…

media_common.quotation_subjectsocial identity theoryhostile media perceptions050801 communication & media studies050109 social psychologySocial identity approachPublic opinion0508 media and communications10240 Department of Communication and Media ResearchPerceptionlanguage and linguisticsMainstream0501 psychology and cognitive sciencesSociologySocial identity theorypopulist attitudesNews media070 News media journalism & publishing1203 Language and Linguisticsmedia_commonbusiness.industrycommunication05 social sciencesMedia studieslinguistics and languagepopulismPopulism3310 Linguistics and Languagefalse consensusFake newsbusiness3315 Communication
researchProduct

Antithrombotics and new interventions for venous thromboembolism: Exploring possibilities beyond factor IIa and factor Xa inhibition.

2021

Abstract Direct oral anti–activated factor X and antithrombin agents have largely replaced vitamin K antagonists as the standard of care in treatment of venous thromboembolism. However, gaps in efficacy and safety persist, notably in end‐stage renal disease, implantable heart valves or assist devices, extracorporeal support of the circulation, and antiphospholipid syndrome. Inhibition of coagulation factor XI (FXI) emerges as a promising new therapeutic target. Antisense oligonucleotides offer potential advantages as a prophylactic or therapeutic modality, with one dose‐finding trial in orthopedic surgery already published. In addition, monoclonal antibodies blocking activation and/or activ…

medicine.drug_class2720 Hematologyvenous thromboembolism610 Medicine & healthBioinformaticslaw.inventionchemistry.chemical_compoundRandomized controlled trialAntiphospholipid syndromelawAntithromboticMedicineDiseases of the blood and blood-forming organsFactor XIIbusiness.industrycatheter(s)Factor X10031 Clinic for AngiologyAntithrombinAnticoagulantanticoagulantHematologycontact systemmedicine.diseasefactor XIPulmonary embolismchemistryRC633-647.5businessState of the Art Isth 2020medicine.drugResearch and practice in thrombosis and haemostasis
researchProduct

INTEGRATED EFFICACY RESULTS FROM THE PHASE 2 AND PHASE 3 STUDIES WITH CAPLACIZUMAB IN PATIENTS WITH ACQUIRED THROMBOTIC THROMBOCYTOPENIC PURPURA

2021

Objective: An integrated analysis based on the Phase 2 TITAN (NCT01151423) and Phase 3 HERCULES (NCT02553317) studies with caplacizumab (CPLZ) in acquired thrombotic thrombocytopenic purpura (aTTP) was performed to assess treatment differences on efficacy and safety outcomes that may have been undetected in the individual trials. Methodology: In both trials, patients with an acute episode of aTTP were randomized to receive CPLZ or placebo (PBO) in addition to therapeutic plasma exchange (TPE) and immunosuppression. All randomized patients from both studies were included in the integrated efficacy analyses (CPLZ: n=108; PBO: n=112), and those who received at least 1 dose of the study drug we…

medicine.medical_specialtyAcquired Thrombotic Thrombocytopenic PurpuraExacerbationbusiness.industrymedicine.medical_treatmentHazard ratioImmunosuppressionHematologyPlaceboGastroenterologyRefractoryInternal medicinemedicineImmunology and AllergyDiseases of the blood and blood-forming organsPlateletRC633-647.5CaplacizumabbusinessHematology, Transfusion and Cell Therapy
researchProduct

Effect of suturing the femoral portion of a four-strand graft during an ACL reconstruction

2014

Purpose A suture passed along the part of the graft that will be inserted into the femoral tunnel is widely used by surgeons, because it could prevent the graft sliding on the femoral fixation device during pulling from the tibial side. The aim of this study was to evaluate the biomechanical effects of suturing the intratunnel femoral part of the graft during an anterior cruciate ligament (ACL) reconstruction. Methods Bovine digital extensor tendons and tibias were harvested from 20 fresh-frozen mature bovine knees ranging in age from 18 to 24 months. Quadruple-strand bovine tendons were passed through the tibial tunnel and secured distally with a bioabsorbable interference screw. In one ha…

medicine.medical_specialtyAnterior cruciate ligamentTransplantsFemoral fixationSettore MED/33 - Malattie Apparato LocomotoremedicineAnimalsOrthopedics and Sports MedicineFemurAnterior Cruciate LigamentFibrous jointFemoral tunnelAnterior Cruciate Ligament Reconstructionbusiness.industrySuture TechniquesBiomechanicsanterior cruciate ligament ACL reconstruction graft properties biomechanics ACL graftmusculoskeletal systemBiomechanical PhenomenaSurgerysurgical procedures operativemedicine.anatomical_structureAcl graftModels AnimalOrthopedic surgeryCattleSurgerybusinessKnee Surgery, Sports Traumatology, Arthroscopy
researchProduct

Guidelines for the management of osteoporosis and fragility fractures

2018

The purpose of this document, a result of the harmonisation and revision of Guidelines published separately by the SIMFER, SIOMMMS/SIR, and SIOT associations, is to provide practical indications based on specific levels of evidence and various grades of recommendations, drawn from available literature, for the management of osteoporosis and for the diagnosis, prevention, and treatment of fragility fractures. These indications were discussed and formally approved by the delegates of the Italian Scientific Associations involved in the project (SIE, SIGG, SIMFER, SIMG, SIMI, SIOMMMS, SIR, and SIOT). The purpose of this document, a result of the harmonisation and revision of Guidelines publishe…

medicine.medical_specialtyBone densityOsteoporosis030204 cardiovascular system & hematologyEM - Original03 medical and health sciences0302 clinical medicineFragilityBone DensitymedicineSettore MED/33 - Malattie Apparato LocomotoreInternal MedicineHumans030212 general & internal medicineFractures; Osteoporosis; Therapy; Internal Medicine; Emergency Medicinebusiness.industryOsteoporosiEvidence-based medicinemedicine.diseaseFractures; Osteoporosis; TherapyFractureItalyFamily medicineEmergency MedicineOsteoporosisTherapybusinessFracturesOsteoporotic Fractures
researchProduct

Thrombosis and thromboembolism related to COVID‐19: A clarion call for obtaining solid estimates from large‐scale multicenter data

2020

Abstract The clinical spectrum of coronavirus disease 2019 (COVID‐19) is wide, ranging from minor, nonspecific symptoms to severe pneumonia, acute respiratory distress syndrome, multiorgan involvement, and shock. In severe cases, the acute systemic inflammatory response, coagulation activation, and diffuse endothelial damage may, in combination with hypoxia, immobilization, and underlying risk factors, result in potentially life‐threatening venous and arterial thrombotic events. The first data from single‐center retrospective studies suggest that thrombotic events are a key aspect of COVID‐19‐associated morbidity and mortality. We have planned and will be launching the COvid REgistry on THR…

medicine.medical_specialtyCoronavirus disease 2019 (COVID-19)Hospitalized patientsvenous thromboembolism610 Medicine & healthAcute respiratory distressregistrymedicine.disease_causeSARS‐CoV‐2COVID‐19Internal medicineMedicineIn patientthrombosisCoronavirusCOVIDbusiness.industryForumlcsh:RC633-647.510031 Clinic for AngiologyRetrospective cohort studyHematologylcsh:Diseases of the blood and blood-forming organsHypoxia (medical)medicine.diseaseThrombosismedicine.symptombusinessResearch and Practice in Thrombosis and Haemostasis
researchProduct

D1 receptors play a major role in the dopamine modulation of mouse ileum contractility

2010

Since the role of dopamine in the bowel motility is far from being clear, our aim was to analyse pharmacologically the effects of dopamine on mouse ileum contractility. Contractile activity of mouse ileum was examined in vitro as changes in isometric tension. Dopamine caused a concentration-dependent reduction of the spontaneous contraction amplitude of ileal muscle up to their complete disappearance. SCH-23390, D1 receptor antagonist, which per se increased basal tone and amplitude of spontaneous contractions, antagonized the responses to dopamine, whilst sulpiride or domperidone, D2 receptor antagonists, were without effects. The application of both D1 and D2 antagonists had additive effe…

medicine.medical_specialtyDopamineMouse ileumD1 receptorIn Vitro TechniquesSettore BIO/09 - FisiologiaEnteric Nervous SystemPotassium channelsContractilityMicechemistry.chemical_compoundDopamine receptor D1IleumDopamineInternal medicineDopamine receptor D2medicineAnimalsPharmacologySCH-23390Dose-Response Relationship DrugReceptors Dopamine D1BenzazepinesAdenosine receptorContractile activityD2 receptorDopamine D2 Receptor AntagonistsEndocrinologychemistryDopamine receptorDopamine AntagonistsEndogenous agonistAdenylyl CyclasesMuscle Contractionmedicine.drugPharmacological Research
researchProduct

CARDIOVASCULAR RISK IN ESSENTIAL THROMBOCYTHEMIA AND POLYCYTHEMIA VERA: THROMBOTIC RISK AND SURVIVAL

2019

Thromboembolic and bleeding events pose a severe risk for patients with Polycythemia Vera (PV) and Essential Thrombocythemia (ET). Many factors can contribute to promoting the thrombotic event due to the interaction between platelets, leukocytes, and endothelium alterations. Moreover, a significant role can be played by cardiovascular risk factors (CV.R) such as cigarette smoking habits, hypertension, diabetes, obesity and dyslipidemia. In this study, we evaluated the impact that CV.R plays on thrombotic risk and survival in patients with PV and ET .

medicine.medical_specialtyEndotheliumGastroenterologySettore MED/15 - Malattie Del Sangue03 medical and health sciences0302 clinical medicinePolycythemia veraInternal medicineDiabetes mellitushemic and lymphatic diseasesmedicinePlateletEssential ThrombocythemiaPolycythemia VeraThrombotic riskEssential thrombocythemiabusiness.industrylcsh:RC633-647.5Hematologylcsh:Diseases of the blood and blood-forming organsmedicine.diseaseObesityPolycythemia vera Essential ThrombocytemiaInfectious Diseasesmedicine.anatomical_structure030220 oncology & carcinogenesisOriginal ArticlebusinessDyslipidemia030215 immunologyMediterranean Journal of Hematology and Infectious Diseases
researchProduct

Using pharmacokinetics for tailoring prophylaxis in people with hemophilia switching between clotting factor products: A scoping review.

2019

Abstract The objective of this scoping review is to summarize the current use of pharmacokinetics for tailoring prophylaxis in hemophilia patients switching between clotting factor products. Patients with hemophilia may require switching of clotting factor concentrates due to a variety of factors, but there have been perceived risks associated with switching, such as inhibitor development or suboptimal protection due to inadequate dosing while titrating treatment. Studies that look at patients switching from one clotting factor concentrate to another are categorized in terms of their primary and/or secondary objectives, notably biosimilarity and comparative pharmacokinetic studies and inhib…

medicine.medical_specialtyFactor concentrate610 Medicine & healthReview Article030204 cardiovascular system & hematologyHemophilia ADrug SubstitutionHemophilia BFactor IX03 medical and health sciencesDrug substitution0302 clinical medicinePharmacokineticsmedicineDosingIntensive care medicineFactor IXClotting factorOriginal Articles: Haemostasisfactor IXFactor VIIIlcsh:RC633-647.5business.industryDosing regimenlcsh:Diseases of the blood and blood-forming organsHematology3. Good healthOnline‐only Articlesfactor VIII3121 General medicine internal medicine and other clinical medicinedrug substitution10032 Clinic for Oncology and Hematologydrug substitution; factor IX; factor VIII; hemophilia A; hemophilia Bhemophilia Bhemophilia Abusiness030215 immunologymedicine.drug
researchProduct